Recombinant factor VIIa versus aPCCs in haemophiliacs with inhibitors: treatment and cost considerations
- 1 March 1999
- journal article
- review article
- Published by Wiley in Haemophilia
- Vol. 5, 43-49
- https://doi.org/10.1046/j.1365-2516.1999.00037.x
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- The use of an activated factor IX complex (Autoplex) in the management of haemarthroses in haemophiliacs with antibodies to factor VIIIClinical and Laboratory Haematology, 2008
- Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa)Blood Coagulation & Fibrinolysis, 1993
- Lingual Hemorrhage in a Patient with Hemophilia A Complicated by a High Titer InhibitorJournal of Pediatric Hematology/Oncology, 1993
- In vitro and in vivo inhibition of monocyte phagocytic function by factor VIII concentrates: correlation with concentrate purityBritish Journal of Haematology, 1990
- Hepatitis C virus transmission by monoclonal antibody purified factor VIII concentrateThe Lancet, 1990
- Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentratesJournal of Medical Virology, 1988
- The Effect of Activated Prothrombin-Complex Concentrate (FEIBA) on Joint and Muscle Bleeding in Patients with Hemophilia A and Antibodies to Factor VIIINew England Journal of Medicine, 1981
- NEW ACTIVATED FACTOR IX PRODUCT IN HAEMOPHILIAThe Lancet, 1980
- Efficacy of Prothrombin-Complex Concentrates in Hemophiliacs with Antibodies to Factor VIIINew England Journal of Medicine, 1980
- Evidence that ‘Activated’ Prothrombin Concentrates Enhance Platelet Coagulant ActivityBritish Journal of Haematology, 1978